Medical Care Technologies (OTC PINK:MDCE) Begins Advanced Internal Beta Testing of MDCE Melanoma Scan Imaging Platform
Rhea-AI Summary
Medical Care Technologies (OTC PINK:MDCE) began advanced internal beta testing of its MDCE Melanoma Scan imaging platform. The AI-assisted system is being evaluated for stability, workflow performance, image management, interface responsiveness, and image consistency.
The beta-stage pre-screening platform supports longitudinal image organization, is part of a broader AI imaging and digital wellness strategy, is not intended to treat or cure disease, and has not been reviewed or cleared by the FDA.
Positive
- Internal beta testing of MDCE Melanoma Scan imaging platform initiated
- Focus on stability, workflow optimization, and image consistency evaluation
- Platform aims to support longitudinal image management workflows
- Development aligned with broader AI-assisted imaging and digital wellness strategy
Negative
- Melanoma Scan platform remains in beta-stage development
- Pre-screening platform not intended to treat, cure, or prevent disease
- Platform has not been reviewed or cleared by the U.S. FDA
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company initiates structured internal testing focused on platform stability, workflow optimization, and image consistency evaluation
MESA, AZ / ACCESS Newswire / June 12, 2026 / Medical Care Technologies, Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), a technology company focused on artificial intelligence, imaging technologies, and digital wellness platforms, today announced the commencement of internal beta testing for its MDCE Melanoma Scan Beta platform.
The testing phase is designed to evaluate platform stability, workflow performance, image management functionality, interface responsiveness, and image consistency processes as the Company continues development of its AI-assisted imaging platform.
The MDCE Melanoma Scan Beta platform is being developed as an image organization and monitoring system intended to support longitudinal image management workflows. Internal testing will focus on identifying opportunities for refinement, validating core platform functions, and optimizing the overall user experience.
"Beginning structured internal testing represents an important milestone in our development process," stated Marshall Perkins, Chief Executive Officer of Medical Care Technologies. "Our focus is on building a stable, scalable, and well-engineered imaging platform through disciplined testing and continuous refinement."
The Company views the platform as part of its broader strategy involving AI-assisted imaging technologies, software infrastructure, and future digital wellness applications.
Medical Care Technologies emphasized that the MDCE Melanoma Scan Beta platform remains in beta-stage development. The pre-screening platform is not intended to treat, cure, or prevent any disease or medical condition and has not been reviewed or cleared by the U.S. Food and Drug Administration.
The Company expects to provide additional updates regarding testing milestones, platform enhancements, and future development initiatives as progress continues.
About Medical Care Technologies, Inc.
Medical Care Technologies, Inc. (OTC PINK:MDCE) is a technology company focused on artificial intelligence, imaging technologies, digital wellness platforms, authentication technologies, and consumer software innovation. The Company is actively developing technology initiatives involving AI-assisted imaging, computer vision, and scalable software platforms.
Contact Information
Medical Care Technologies, Inc.
Website: https://medicalcaretechnologies.com/
Email: info@medicalcaretechnologies.com
Phone: 1-480-645-0750
Address: 1910 S Stapley Drive, Suite 221, Mesa, AZ 85204
Safe Harbor Statement
This press release contains forward-looking statements that involve risks and uncertainties. These statements include, but are not limited to, expectations regarding product development, testing activities, technology initiatives, future enhancements, and business strategy. Actual results may differ materially from those projected. Medical Care Technologies undertakes no obligation to update forward-looking statements except as required by law.
SOURCE: Medical Care Technologies Inc.
View the original press release on ACCESS Newswire